Sep 14, 2022 / 03:00PM GMT
Matt Keller - HC Wainwright - Analyst
Good morning, everyone, and welcome to the third day of the HC Wainwright 24th Annual Investment Conference. My name is Matt Keller, and I'm associate in the equity research department. And I'll be the moderator for your session.
Now with that, please walk me -- or join me in welcoming our next presenter, Armon Sharei, the CEO of SQZ Biotechnologies. So with that, Armon, please take it away.
Armon Sharei - SQZ Biotechnologies Company - CEO & Founder
Right. Thanks for that, Matt, and thanks to the HC Wainwright team for having us. I'm excited today to talk about SQZ and all the latest that we've been up to with our cell therapy platform.
Just as an overview for SQZ. As far as brief highlights, the company has founded around a new technology to deliver materials into cells, which tries to solve some of the fundamental issues people have as far as how you can actually engineer cell therapies and use that to pursue different biologics while also improving on the scalability and cost effectiveness of the
SQZ Biotechnologies Co at H C Wainwright Global Investment Conference (Virtual) Transcript
Feb 15, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers